29-May-2026
No press releases found.
Market Chameleon (Thu, 20-Nov 6:51 AM ET)
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.
State Street SPDR S&P Biotech ETF trades on the ARCA stock market under the symbol XBI.
As of May 29, 2026, XBI stock price climbed to $136.69 with 6,283,688 million shares trading.
XBI has a beta of 0.90, meaning it tends to be less sensitive to market movements. XBI has a correlation of 0.26 to the broad based SPY ETF.
XBI has a market cap of $8.32 billion. This is considered a Mid Cap stock.
In the last 3 years, XBI traded as high as $139.19 and as low as $63.80.
XBI has outperformed the market in the last year with a price return of +70.4% while the SPY ETF gained +29.5%. However, in the short term, XBI had mixed performance relative to the market. It has underperformed in the last 3 months, returning +7.3% vs +10.5% return in SPY. But in the last 2 weeks, XBI shares have fared better than the market returning +4.6% compared to SPY +2.3%.
XBI support price is $133.49 and resistance is $138.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBI shares will trade within this expected range on the day.